FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease
Open Access
- 21 April 2010
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 85 (5), 315-319
- https://doi.org/10.1002/ajh.21656
Abstract
On June 30, 2009, the United States Food and Drug Administration (FDA) approved ferumoxytol (Feraheme™ injection, AMAG Pharmaceuticals), an iron‐containing product for intravenous (IV) administration, for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). The safety and efficacy of ferumoxytol were assessed in three randomized, open‐label, controlled clinical trials. Two trials evaluated patients with nondialysis dependent CKD and a third trial assessed patients undergoing hemodialysis. Randomization was either to ferumoxytol or oral iron. Ferumoxytol was administered as two 510 mg IV injections, separated by 3–8 days. Oral iron, Ferro‐Sequels®, was administered at a dose of 100 mg twice daily for 21 days. In all three clinical trials, ferumoxytol administration increased the mean blood hemoglobin (Hgb) concentrations by ∼1.0 g/dL over the 35 day period, a mean increase that was greater than what was observed in patients receiving oral iron. Patients receiving ferumoxytol also had increases in blood transferrin saturation (TSAT) and ferritin values. For the proposed ferumoxytol dosing regimen, 4.9% of patients had serum ferritin ≥800 ng/mL and TSAT ≥50% post‐treatment. The most important ferumoxytol safety concerns were hypersensitivity reactions and/or hypotension. Anaphylaxis or anaphylactoid reactions were reported in 0.2% of subjects, and other adverse reactions potentially associated with hypersensitivity (e.g., pruritus, rash, urticaria, or wheezing) were reported in 3.7%. Hypotension was observed in 1.9%, including three patients with serious hypotensive reactions. Ferumoxytol administration may transiently affect the diagnostic ability of magnetic resonance imaging and the drug label provides further information regarding this effect. Am. J. Hematol. 2010. Published 2010 Wiley‐Liss, Inc.Keywords
This publication has 29 references indexed in Scilit:
- KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 UpdateAmerican Journal of Kidney Diseases, 2009
- Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2009
- Safety Issues With Intravenous Iron Products in the Management of Anemia in Chronic Kidney DiseaseClinical Medicine & Research, 2008
- Safety of Ferumoxytol in Patients With Anemia and CKDAmerican Journal of Kidney Diseases, 2008
- Ferumoxytol as a New, Safer, Easier-to-Administer Intravenous Iron: Yes or No?American Journal of Kidney Diseases, 2008
- Comparing the efficacy of intravenous iron and oral iron in nondialysis patients with chronic kidney diseaseNature Clinical Practice Nephrology, 2008
- Iron therapy for renal anemia: how much needed, how much harmful?Pediatric Nephrology, 2007
- Oxidative stress and renal injury with intravenous iron in patients with chronic kidney diseaseKidney International, 2004
- Indices of iron status in continuous ambulatory peritoneal dialysis patientsAmerican Journal of Kidney Diseases, 1999
- Effectiveness and Safety of Recombinant Human Erythropoietin in Predialysis PatientsNephron, 1992